Table 6.
Biomarker Test Specifics | No. of Patients (%) | Sensitivity, % (95% CI) | Specificity, % (95% CI) | PPV, % (95% CI) | NPV, % (95% CI) | Likelihood Ratio | P Value |
---|---|---|---|---|---|---|---|
All children | |||||||
Pyrazinamide peak <38.10 mg/L | 127 (89) | 76 (58–89) | 68 (58–77) | 45 (32–59) | 89 (79–95) | 2.374 | <.001 |
Pyrazinamide peak <38.10 mg/L plus rifampin peak <3.20 mg/L | 143 (100) | 52 (34–69) | 89 (82–94) | 59 (39–76) | 86 (78–92) | 4.722 | <.001 |
Children <3 y old | |||||||
Isoniazid AUC0–24 < 11.95 mg/L × h | 18 (13) | 86 (42–100) | 82 (48–98) | 75 (35–97) | 90 (56–100) | 4.714 | .041 |
Isoniazid AUC0–24 threshold plus rifampin peak <3.10 mg/L | 18 (13) | 86 (42–100) | 75 (35–97) | 75 (35–97) | 86 (42–100) | 3.429 | .041 |
Italics values represent P-values <.05.
Abbreviations: AUC0–24, 24-hour area under the concentration time curve; CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value.